The estimated Net Worth of Coleman N Iii Lannum is at least 1.02 千$ dollars as of 9 June 2017. Coleman Lannum owns over 2,950 units of Mallinckrodt Plc stock worth over 1,020$ and over the last 10 years Coleman sold MNK stock worth over 0$.
Coleman has made over 22 trades of the Mallinckrodt Plc stock since 2015, according to the Form 4 filled with the SEC. Most recently Coleman bought 2,950 units of MNK stock worth 117,499$ on 9 June 2017.
The largest trade Coleman's ever made was buying 2,950 units of Mallinckrodt Plc stock on 9 June 2017 worth over 117,499$. On average, Coleman trades about 698 units every 25 days since 2015. As of 9 June 2017 Coleman still owns at least 3,000 units of Mallinckrodt Plc stock.
You can see the complete history of Coleman Lannum stock trades at the bottom of the page.
Coleman's mailing address filed with the SEC is McDonnell Boulevard, Hazelwood, Saint Louis County, Missouri, 63042, United States.
Over the last 11 years, insiders at Mallinckrodt Plc have traded over 29,853,069$ worth of Mallinckrodt Plc stock and bought 2,559,592 units worth 174,429,961$ . The most active insiders traders include & Co. Inc. Paulson、James E Deerfield Mgmt L.P....、Nancy Lurker. On average, Mallinckrodt Plc executives and independent directors trade stock every 29 days with the average trade being worth of 10,061$. The most recent stock trade was executed by Jason Daniel Goodson on 16 March 2023, trading 1,133 units of MNK stock currently worth 9,495$.
mallinckrodt is a global specialty biopharmaceutical and medical imaging business that develops, manufactures, markets and distributes specialty pharmaceutical products and medical imaging agents. areas of focus include therapeutic drugs for autoimmune and rare disease specialty areas like neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal respiratory critical care therapies; and analgesics and central nervous system drugs. the company's core strengths include the acquisition and management of highly regulated raw materials; deep regulatory expertise; and specialized chemistry, formulation and manufacturing capabilities. the company's specialty brands segment includes branded medicines; its specialty generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the global medical imaging segment includes contrast media and nuclear imaging agents. to learn more about mallinckrodt, visit
Mallinckrodt Plc executives and other stock owners filed with the SEC include: